Semaglutide Side Effects: The Complete, Honest Guide

The most common semaglutide side effects are gastrointestinal: nausea (affects roughly 40–44% of patients), diarrhea (20–30%), vomiting (14–24%), and constipation (10–24%). These are dose-related — they occur most frequently during the first few weeks after a dose increase and diminish significantly once the body adjusts. Headache (10–14%) and injection site reactions are also commonly reported early in treatment.

No — nausea from semaglutide is almost never permanent. In the STEP clinical trials, nausea was most common in the first 4 to 8 weeks, peaked during early dose escalations, then steadily declined. By months 4 to 6, most patients report minimal or no nausea. The slow 5-step titration schedule exists specifically to reduce nausea risk. If nausea remains severe after 6 to 8 weeks at any dose, ask your prescriber about extending the titration interval rather than increasing further.

The side effect profiles of semaglutide and tirzepatide are broadly similar — both are dominated by GI effects that resolve with time. Some clinical data suggests semaglutide may produce slightly higher rates of nausea and headache compared to tirzepatide at equivalent weight-loss doses, possibly because tirzepatide's added GIP receptor activation partially counteracts some GLP-1-related GI effects. However, both medications are well-tolerated by the majority of patients when properly titrated, and individual experience varies widely.

Hair loss (telogen effluvium) is reported by some semaglutide users, affecting an estimated 5 to 10% of patients. This is not caused by semaglutide itself — it's a well-documented response to rapid weight loss in general. When the body loses weight quickly, it can redirect resources away from non-essential functions like hair growth. This type of hair loss is typically temporary, peaking around 3 to 6 months after rapid weight loss begins and reversing naturally. Adequate protein intake (0.7 to 1 g per pound of body weight daily) is the most evidence-supported prevention strategy.

Pancreatitis is listed as a warning in semaglutide's prescribing information, but the real-world incidence is very low — approximately 0.1% or less across clinical trial populations. The STEP and SUSTAIN trials did not demonstrate a statistically significant increase in pancreatitis compared to placebo. That said, if you have a personal or family history of pancreatitis, semaglutide requires careful prescriber evaluation before starting. Severe, persistent abdominal pain that radiates to the back should always prompt immediate medical attention.

Ozempic face — also called GLP-1 face — is a colloquial term for facial volume loss that some patients notice with significant weight loss on semaglutide. It's not a unique pharmaceutical side effect; it's the result of fat loss from the face, which shows more prominently in some people. Losing 15%+ of body weight changes facial fullness. This occurs with any significant weight loss, not specifically semaglutide. Maintaining adequate nutrition, staying hydrated, and incorporating strength training to preserve muscle tone can minimize the appearance of facial volume loss.

This is widely misunderstood. Thyroid C-cell tumors were observed in rodent studies at doses far higher than used clinically in humans. However, humans have significantly fewer GLP-1 receptors in thyroid tissue than rodents, and years of post-market surveillance across millions of patients have not confirmed a causal link between semaglutide and thyroid cancer in humans. Semaglutide (and all GLP-1 medications) is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). For everyone else, the available data does not show an elevated human risk.

Fatigue in the early weeks of semaglutide is common and usually has a clear explanation. When calorie intake drops significantly — which semaglutide causes naturally by reducing appetite — your body adjusts its energy balance, which can cause temporary tiredness. Blood sugar fluctuations as insulin sensitivity improves can also cause brief energy dips. The fatigue almost always resolves within the first 4 to 8 weeks as eating patterns stabilize. Make sure you are consuming adequate calories (typically no lower than 1,200 to 1,400 kcal daily), staying hydrated, and getting 7 to 9 hours of sleep.

Yes — the vast majority of patients manage nausea successfully without stopping semaglutide. Evidence-supported strategies include: eating small, slow meals every 3 to 4 hours rather than large ones; avoiding fatty, greasy, or spicy food; staying well hydrated between (not during) meals; taking the injection at bedtime to sleep through peak nausea hours; avoiding lying flat after eating; and trying ginger tea or ginger chews. If these measures aren't enough, speak with your prescriber about an over-the-counter anti-nausea option. Extending the current dose interval rather than advancing is often the most effective approach.

For severe or persistent vomiting or diarrhea — especially if you cannot keep fluids down for 24 hours — contact your prescriber or seek medical care. For severe abdominal pain (especially if it radiates to the back), stop the medication and go to the emergency room. For signs of an allergic reaction (facial swelling, breathing difficulty, severe rash), call 911. For persistent but non-emergency side effects significantly impacting your quality of life, contact your prescriber to discuss dose reduction or extended titration intervals.